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reported and it is not possible to determine if the best available evidence was used. The sensitivity and specificity estimates appeared to be based on good studies, but only limited details were provided and no quality assessment was undertaken. The utility estimates were satisfactorily reported and based on a number of potentially good sources. These were augmented by the authors' professional judgements, which were appropriately tested in sensitivity analyses. Only limited details of the primary studies were given. The authors reported that the time trade-off method was used to derive the utilities, but they provided no details of whose preferences were measured.
Costs:
The perspective was stated to be societal, but it is not clear that this was correct. A previous study had shown that breast cancer did not significantly affect a woman's wages, which could justify the exclusion of productivity losses, but only the benefits and costs incurred by the patient were evaluated and so many of the costs that you would expect to see evaluated from a societal perspective were not considered. The cost estimates were well reported and came from what appear to have been relevant and reliable sources. The price year, inflation using the medical care component of the Consumer Price Index, and discounting were all appropriately reported.
Analysis and results:
The analytical approach was well reported and the semi-Markov model used to estimate the costs and effects from both strategies was valid. The results were reported clearly and in full. The issue of uncertainty was addressed through univariate sensitivity analyses and probabilistic sensitivity analysis and a confidence ellipse and cost-effectiveness acceptability curve were presented. The sensitivity analysis results for the sensitivity and specificity of testing were not reported (see note). The authors highlighted the impact of inconclusive results on the cost-effectiveness and the fact that cancer and preventive surgery utilities might now be higher since the estimates were based on studies published between 1999 and 2005.
Note: after this abstract was published the following additional information was provided by the authors. "Due to space limitations, we reported the value ranges used for all variables included in the sensitivity analysis, but
detailed sensitivity results were reported only for the four variables to which the model was most sensitive. Therefore, although the sensitivity of the model to the sensitivity and specificity of testing was not directly reported, it was implied that the model was less sensitive to those than to the variables discussed on page 212 of the paper. In addition, sensitivity and specificity variation was included in the probabilistic sensitivity model."
Concluding remarks:
: The methods were satisfactory, but the lack of reporting of a literature review and the analysis of the sensitivity and specificity of genetic testing, makes it difficult to assess whether the authors' conclusions are robust. Given the impact of considering inconclusive results on the cost-effectiveness, the authors' conclusions should be considered with caution.
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